GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South Korean company’s tech to bypass the blood-brain barrier. | GSK has continued ...

Shortly after President Donald Trump took office this January, the White House rolled out an initiative designed to slash ...

Relay Therapeutics has laid off about 70 employees, the biotech's third round of cuts in less than a year.  | Relay ...

After a drawn-out acquisition that closed in 2023, U.K. biotech F-star Therapeutics is charting its own path as a private, ...

Neurona Therapeutics has circled up $102 million to push its off-the-shelf cell therapy for epilepsy through phase 3 testing.

Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...

The cuts impact more than $2.4 billion in grant money, including $1.3 billion in grant funds already spent on projects ...

Home CPAP device maker Resmed is launching a small, disposable wearable to help diagnose cases of obstructive sleep apnea.  | ...

Brown University has reportedly become the fifth university to be targeted by the Trump administration for funding cuts, ...

The FDA has set back Aldeyra Therapeutics’ ambitions to win approval for its dry eye disease, rejecting its second ...

In this week’s episode of "The Top Line," Fierce Biotech’s Gabrielle Masson and Darren Incorvaia sit down to discuss a recent ...

After a year of stripping back its head count and pipeline, Carisma Therapeutics is now cutting down to the bone and laying ...